41125-09-1

Basic information

• Product Name: 3-oxo-butyraldehyde; sodium enolate
• CAS NO: 41125-09-1
• Molecular Weight: 108.072
• Mol File: 41125-09-1.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 3-oxo-butyraldehyde; sodium enolate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-oxo-butyraldehyde; sodium enolate(41125-09-1)
• EPA Substance Registry System: 3-oxo-butyraldehyde; sodium enolate(41125-09-1)

Safety Data

• Hazardous Substances Data: 41125-09-1(Hazardous Substances Data)

Upstream product

• 67-64-1 acetone 
• 109-94-4 formic acid ethyl ester 
• 107-31-3 Methyl formate 
• 201230-82-2 carbon monoxide 
• 124-41-4 sodium methylate 

Downstream Products

• 53133-27-0 4-(N-methyl-anilino)-but-3-en-2-one 
• 31172-37-9 trans-4-methoxybut-3-en-2-one 
• 39745-39-6 6-methyl-3-nitrohydropyridin-2-one 
• 20082-91-1 4,4-diethoxybutan-2-one 
• 65169-38-2 2-chloro-4-methyl-3-pyridinecarbonitrile 
• 5436-21-5 acetylacetaldehyde dimethyl acetal 
• 4652-27-1 4-methoxy-3-buten-2-one 
• 50423-37-5 1,3,5-tris-(3-phenyl-propionyl)-benzene 
• 56505-80-7 houttuynin 
• 623-38-1 1,3-pentanedione 
• 4241-27-4 1,2-dihydro-6-methyl-2-oxo-3-pyridinecarbonitrile 
• 59951-32-5 (Z)-4-(cyclohexylamino)but-3-en-2-one 
• 92676-71-6 (Z)-4-(allylamino)but-3-en-2-one 
• 92676-72-7 cis-1-isopropylamino-1-buten-3-one 

Relevant articles and documents

Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of zeste homologue 2) inhibitors and anticancer agents

Zeste enhancer homolog 2 (EZH2) is highly expressed in various malignant tumors, which could silence tumor suppressor genes via trimethylation of H3K27. Herein was first reported a novel series of pyrrole-3-carboxamide derivatives carrying a pyridone fragment as EZH2 inhibitors. By combining computational modeling, in vitro cellular assays and further rational structure-activity relationship exploration and optimization, compound DM-01 showed powerful inhibition towards EZH2. DM-01 was found to have significant ability to reduce the cellular H3K27me3 level in K562 cells in the Western blot test. Meanwhile, our data showed that knockdown EZH2 in A549 cells resulted in a decrease of cell sensitivity to DM-01 at 50 and 100 μM. DM-01 could also increase the transcription expression of DIRAS3 in a dose-dependent manner, a tumor suppressor in the downstream of EZH2, suggesting it was worth investigating further as a lead compound.

Pyrrole-3-formamide compound as well as preparation method and application thereof

The invention belongs to the technical field of medicines, and relates to a pyrrole-3-formamide compound as well as a preparation method and application thereof, in particular to a pyrrole-3-formamidecompound shown as a formula (I) or (II) and a pharmaceutically-acceptable salt thereof, wherein R to R and X are defined in the claims and description. The preparation of the compound mainly comprises performing Knorr pyrrole synthesis, Hantzsch pyrrole synthesis, decarboxylation, alkylation, hydrolysis, condensation, cyclization and reduction on ethyl acetoacetate or tert-butyl acetoacetate serving as the raw material. The pyrrole-3-formamide compound and the pharmaceutically-acceptable salt thereof have good treatment effects on tumors, and can be applied to the preparation of anti-tumor drugs. (The formulas (I) and (II) are shown in the description).

MANUFACTURE OF HYDRAZINYL COMPOUNDS USEFUL IN THE MANUFACTURE OF PYRAZOLE CARBOXYLIC ACID AND DERIVATIVES, HYDRAZINYL COMPOUNDS AND THEIR USE

The present invention concerns the manufacture of hydrazinyl compounds useful in the manufacture of pyrazole carboxylic acid and derivatives thereof and processes for the manufacture of agrochemical or pharmaceutical compounds. The invention also concerns hydrazinyl compounds and their use.